| Inventiva secures the €116 million second tranche of its structured financing of up to €348 million |
Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the “Structured Financing”), for gross proceeds of €115.6 million (net proceeds of €108.5 million) (the “T2 Transaction”). |
globenewswire.com |
2025-05-05 06:30:00 |
Czytaj oryginał (ang.) |
| Combined General Meeting of May 22, 2025 - Availability of the preparatory documents |
Daix (France), New York City (New York, United States), April 30, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of May 22, 2025. |
globenewswire.com |
2025-04-30 20:00:00 |
Czytaj oryginał (ang.) |
| Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor |
► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis |
globenewswire.com |
2025-04-24 20:01:00 |
Czytaj oryginał (ang.) |
| Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F |
Daix (France), New York City (New York, United States), April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that it had filed its 2024 Universal Registration Document for the year ended December 31, 2024, including the management report and the annual financial report, with the French “Autorité des Marchés Financiers” (“AMF”) and its 2024 Annual Report on Form 20-F for the year ended December 31, 2024 with the U.S. Securities and Exchange Commission (“SEC”). |
globenewswire.com |
2025-04-15 20:00:00 |
Czytaj oryginał (ang.) |
| Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis |
Daix (France), New York City (New York, United States), April 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced the completion of patient enrollment in its NATiV3 Phase 3 clinical trial with the randomization of the last patient in the main cohort. Inventiva has enrolled 1009 patients in the main cohort and 410 patients in the exploratory cohort exceeding the original target of 969 and 350, respectively. |
globenewswire.com |
2025-04-01 21:00:00 |
Czytaj oryginał (ang.) |
| Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript |
Inventiva S.A. (NASDAQ:IVA ) Q4 2024 Earnings Call March 27, 2025 8:00 AM ET Company Participants Frédéric Cren - CEO Jean Volatier - CFO Pierre Broqua - CSO Conference Call Participants Unidentified Analyst - TD Cowen Unidentified Analyst - Jefferies & Co. Annabel Samimy - Stifel Ed Arce - HC Wainwright Jacob Mekhael - KBC Securities Rami Katkhuda - LifeSci Capital Unidentified Analyst - UBS Operator Good day and thank you for standing by. |
seekingalpha.com |
2025-03-27 12:50:21 |
Czytaj oryginał (ang.) |
| Inventiva reports its 2024 full year results and provides a business update |
Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), and other diseases with significant unmet medical needs, today reported its financial results for the full year ended December 31, 2024 and also provided a business update. |
globenewswire.com |
2025-03-26 18:00:00 |
Czytaj oryginał (ang.) |
| Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results |
Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. |
globenewswire.com |
2025-03-19 18:00:00 |
Czytaj oryginał (ang.) |
| Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment |
Daix (France), New York City (New York, United States), February 26, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced the publication in Biomedicine & Pharmacotherapy, a peer-reviewed, scientific journal, of the results from a preclinical study demonstrating that lanifibranor may reduce Portal Hypertension (“PH”). |
globenewswire.com |
2025-02-26 18:00:00 |
Czytaj oryginał (ang.) |
| Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial |
Daix (France), New York City (New York, United States), Tokyo (Japan), February 20, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, and Hepalys Pharma, Inc. (“Hepalys”), a company incorporated in Japan and founded by Catalys Pacific, announced today the initiation of the clinical development program of lanifibranor in Japan with the first Japanese participant dosed in a Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics (“PK”) and pharmacodynamics (“PD”) of lanifibranor. |
globenewswire.com |
2025-02-20 18:00:00 |
Czytaj oryginał (ang.) |
| Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update |
Daix (France), New York City (New York, United States), February 10, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), and other diseases with significant unmet medical needs, today reported certain preliminary unaudited financial results for the full year ended December 31, 2024, including cash, cash equivalents, and revenues, and also provided a business update. |
globenewswire.com |
2025-02-10 18:00:00 |
Czytaj oryginał (ang.) |
| Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology |
Daix (France), New York City (New York, United States), January 29, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced the publication in Journal of Hepatology, a peer-reviewed scientific journal, of the results from the investigator-initiated clinical study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with type 2 diabetes (“T2D”) and Metabolic dysfunction-Associated Liver Disease (“MASLD”)1. The clinical trial demonstrated significant improvement of hepatic, muscle and adipose tissue insulin resistance in patients with MASLD and T2D treated with lanifibranor. |
globenewswire.com |
2025-01-29 18:00:00 |
Czytaj oryginał (ang.) |
| Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux |
Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux. |
globenewswire.com |
2025-01-24 18:00:00 |
Czytaj oryginał (ang.) |
| Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025 |
Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that the results from its Proof-of-Concept trial evaluating lanifibranor in combination with empagliflozin for the treatment of MASH have been selected to be presented by Dr. Onno Holleboom in an oral plenary presentation at the upcoming Steatotic Liver Disease (SLD) Summit 2025 hosted by the European Association for the Study of the Liver (EASL) on January 23-25 in Estoril, Portugal. |
globenewswire.com |
2025-01-22 18:00:00 |
Czytaj oryginał (ang.) |
| Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference |
Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that Frédéric Cren, CEO and cofounder of Inventiva, has been invited to present a corporate overview, and will engage, with Inventiva's leadership team, in investor meetings at the upcoming 43rd Annual J.P. Morgan Annual Healthcare Conference, being held on January 13-16, 2025 at the Westin St. Francis in San Francisco, California. |
globenewswire.com |
2024-12-17 18:00:00 |
Czytaj oryginał (ang.) |
| Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million |
Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that, following the general meeting of the shareholders held on December 11, 2024 (the “General Meeting”), the Board of Directors decided to use the delegations granted by the General Meeting to issue the second phase of Tranche 1 (the “T1 bis Transaction”) for a gross amount of €21.4 million (net amount of €20.1 million) of the multi-tranche equity financing of up to €348 million announced on October 14, 2024 (the “Multi-Tranche Financing”). |
globenewswire.com |
2024-12-16 04:30:00 |
Czytaj oryginał (ang.) |
| Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024 |
Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined Shareholders' Meeting. |
globenewswire.com |
2024-12-12 18:00:00 |
Czytaj oryginał (ang.) |
| Inventiva reports 2024 Third Quarter Financial Information¹ |
Daix (France), New York City, (New York, United States), November 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today reported its cash position as of September 30, 2024 and its revenues for the first nine months of 2024. |
globenewswire.com |
2024-11-21 18:00:00 |
Czytaj oryginał (ang.) |
| Combined General Meeting of December 11, 2024 - Availability of the preparatory documents |
Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of December 11, 2024. |
globenewswire.com |
2024-11-20 18:00:00 |
Czytaj oryginał (ang.) |
| Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams |
CHICAGO--(BUSINESS WIRE)--Alight is integrating Alight Worklife® with Microsoft Teams, enabling seamless access to benefits and wellbeing info within the Teams platform. |
businesswire.com |
2024-11-18 10:30:00 |
Czytaj oryginał (ang.) |
| Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session |
Daix (France), Long Island City (New York, United States), November 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the presentation of the final analysis of LEGEND, Phase 2 proof-of-concept clinical trial, evaluating lanifibranor in combination with empagliflozin in patients with MASH and Type 2 Diabetes (T2D). The data will be presented Monday November 18, 2024, as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in San Diego California. |
globenewswire.com |
2024-11-15 18:00:00 |
Czytaj oryginał (ang.) |
| Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH |
Daix (France), Long Island City (New York, United States), November 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the positive recommendation from the fifth scheduled meeting of the Data Monitoring Committee (“DMC”) to continue the NATiV3 Phase 3 clinical trial evaluating lanifibranor in patients with MASH without modification to the current trial protocol. |
globenewswire.com |
2024-10-30 18:00:00 |
Czytaj oryginał (ang.) |
| Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024 |
Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), today announced that the results of the Phase 2, LEGEND, evaluating lanifibranor in combination with empagliflozin in patients with MASH and Type-2-Diabetes (“T2D”) has been accepted as late breaker by the scientific committee of the upcoming 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 being held November 15 to 19, 2024 in San Diego, California. |
globenewswire.com |
2024-10-21 12:30:00 |
Czytaj oryginał (ang.) |
| Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants |
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announces that the Autorité des marchés financiers (the “AMF”) has approved a prospectus under no. 24-432, on October 14, 2024, in connection with its financing through the issuance of ordinary shares and pre-funded share warrants |
globenewswire.com |
2024-10-14 17:45:00 |
Czytaj oryginał (ang.) |
| Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report |
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the filing, for the six-month period ended June 30, 2024 of its Half-Year Report (the “2024 Half-Year Report”) with the French financial markets authority, “Autorité des Marchés Financiers” (“AMF”). |
globenewswire.com |
2024-10-14 06:35:00 |
Czytaj oryginał (ang.) |
| Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study |
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced financing of immediately €94.1 million and up to €348 million (the “Transaction”), subject to satisfaction of specified conditions, to fund the completion of the Phase 3 NATiV3 MASH trial and preparation for the potential filing for marketing approval and commercialization of lanifibranor. |
globenewswire.com |
2024-10-14 06:30:00 |
Czytaj oryginał (ang.) |
| Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-10-01 14:36:07 |
Czytaj oryginał (ang.) |
| Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results |
Daix (France), Long Island City (New York, United States), September 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today provided a corporate and a financial update for the six months ended June 30, 2024. |
globenewswire.com |
2024-09-25 20:00:00 |
Czytaj oryginał (ang.) |
| Inventiva Reports Preliminary 2024 First-Half Financial Information¹ |
Daix (France), Long Island City (New York, United States), July 31, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today reported certain preliminary financial results for the first half of 2024, including its cash, cash equivalents, and revenues. |
globenewswire.com |
2024-07-31 20:00:00 |
Czytaj oryginał (ang.) |
| Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor |
Daix (France), Long Island City (New York, United States), July 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that the Japan Patent Office (“JPO”) has approved Inventiva's patent application No. JP 2019-203498, protecting the use of lanifibranor for the treatment of patients with cirrhosis. This new patent will be valid until November 8, 2039, excluding any potential patent term adjustments or extensions that may provide additional protection. |
globenewswire.com |
2024-07-25 20:00:00 |
Czytaj oryginał (ang.) |
| Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux |
Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux. |
globenewswire.com |
2024-07-19 15:30:00 |
Czytaj oryginał (ang.) |
| Inventiva announces a €20.1 million issuance of royalty certificates |
Daix (France), Long Island City (New York, United States), July 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the issuance of royalty certificates (the “Royalty Certificates”) subscribed by Samsara BioCapital, BVF Partners, NEA, Sofinnova, and Yiheng, for an amount of approximately €20.1 million (the “Transaction”). |
globenewswire.com |
2024-07-18 06:30:00 |
Czytaj oryginał (ang.) |
| Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement |
Inventiva S.A. top-line results from phase 3 NATiV3 study, using lanifibranor for the treatment of patients with MASH, expected by 2nd half of 2026. The 4th pass of the safety review of the DMC was conducted, and it was noted that the phase 3 NATiV3 study should continue without modification. The global non-alcoholic steatohepatitis market is expected to reach $48.3 billion by the end of 2035. |
seekingalpha.com |
2024-07-08 18:36:33 |
Czytaj oryginał (ang.) |
| Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position |
Daix (France), Long Island City (New York, United States), July 5, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today provided an update on its clinical program evaluating lanifibranor for the treatment of MASH/NASH and its financial position. |
globenewswire.com |
2024-07-05 20:00:00 |
Czytaj oryginał (ang.) |